Scott WilliamsNuclear MedicineTumor ImagingProstascint (111In-Capromab Pendetide) (CYT-356)Scott WilliamsApr 2, 2002Prostascint (111In-Capromab Pendetide) (CYT-356) Clinical problem Chemistry and pharmacology Imaging Protocol Interpretation Indications for the exam Dosimetry Complications/Side Effects HAMA Formation (Immunogenicity)Latest in Tumor ImagingTumor > Therapy > Xofigo and other Prostate AgentsAugust 16, 2017Tumor > Therapy > Xofigo and PSMA therapiesJanuary 26, 2015SponsoredDigital Innovations Shaping the Future of RadiologySeptember 24, 2025Tumor > Therapy > MicrospheresJanuary 31, 2008Related StoriesNuclear MedicineProstascint (111In-Capromab Pendetide) (CYT-356)Nuclear MedicineTc-99m-Arcitumomab (CEA-Scan)Tumor ImagingThallium Tumor Imaging:Sponsor ContentDigital Innovations Shaping the Future of Radiology